This symposium took place on 12th June 2016, as a part of the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2016 in Vienna, Austria
Chairperson: Matthias Kramer1
Speakers: Ralph Mösges,2 Randolf Brehler,3 Thomas Kündig4
1. Allergy Therapeutics, Worthing, UK
2. Institute of Medical Statistics, Epidemiology and Computer Science, University Hospital Cologne, Cologne, Germany
3. Department of Dermatology, University Hospital, Münster, Germany
4. Department of Dermatology, Zurich University Hospital, Zurich, Switzerland
Disclosure: Prof Matthias Kramer is an employee of Allergy Therapeutics UK Ltd. Prof Ralph Mösges has received consulting and/or speaker’s fees from, and/or conducted contract research for, several companies including ALK, Allergopharma, Bencard, Dr Beckmann, BioTechTools, HAL, Leti, Lofarma, Novartis, Roxall, Merck, and Stallergènes. Prof Randolf Brehler has received consulting and/or speaker‘s fees from Bencard, ALK, Allergopharma, Almirall, Basilea, Dr Pfleger, Hal, Leti, MSD, MEDA, Novartis, Pierre Fabre, Pohl Boskamp, Siemens, Stallergènes, and Thermo-Fischer. Dr Thomas Kündig has received consulting and speaker’s fees from Allergy Therapeutics.
Acknowledgements: Writing assistance was provided by Tabasum Mughal of ApotheCom.
Support: The symposium was sponsored by Allergy Therapeutics. Authors received honoraria for preparation and delivery of their presentations. The views and opinions expressed are those of the authors and not necessarily of Allergy Therapeutics.
Citation: EMJ Allergy Immunol. 2016;1:32-36.
This symposium provided an overview of the current and future technologies and treatments used in the field of allergen immunotherapy (AIT). Prof Ralph Mösges explored the concept of pre-seasonal immunotherapy in overcoming the problem of recurrent allergy, focussing on the use of Pollinex® Quattro versus the use of symptomatic treatment according to current guidelines. The use and mechanisms of adjuvants was explored by Prof Randolf Brehler, who discussed the use of adjuvants in AIT including delivery systems, immunopotentiators, and targeted delivery systems to facilitate optimum immune responses with the potential of a lower injection burden and increased efficacy of treatment. Prof Thomas Kündig concluded the symposium with an overview of the future of AIT and the use of virus-like particles (VLP) in harnessing the innate immune system response to protect against allergens.